Table 3.
The outcomes of patients in three groups.
| NV group (n = 31) | OV group (n = 21) | TV group (n = 60) | p value | |
|---|---|---|---|---|
| Oxygen support | 27 (87) | 19 (91) | 58 (97) | 0.22 |
| No-drug used | 4 (13) | 2 (10) | 11 (18) | <0.001 |
| Anticoagulation | 16 (52) | 11 (52) | 36 (60) | 0.69 |
| Antibodies/convalescent plasma | 0 (0) | 0 (0) | 0 (0) | NA |
| Thymalfasin | 2 (7) | 2 (10) | 4 (7) | 0.89 |
| Lopinavir/ritonavir | 0 (0) | 0 (0) | 1 (2) | 0.65 |
| Hospital stay (d) | 17.6 ± 4.4 | 17.1 ± 3.5 | 14.4 ± 2.2 | <0.01 |
| Viral clearance time (d) | 14.3 ± 3.6 | 13.8 ± 3.6 | 11.2 ± 1.9 | <0.001 |
| Time to peak (d) | 4.8 ± 2.8 | 4.8 ± 2.9 | 3.5 ± 2.2 | 0.03 |
| Symptom recovery | ||||
| Stuffy nose/snot | 0 (0) | 0 (0) | 0 (0) | NA |
| Sore throat | 0 (0) | 0 (0) | 0 (0) | NA |
| Cough | 0 (0) | 0 (0) | 0 (0) | NA |
| Sputum production | 0 (0) | 0 (0) | 0 (0) | NA |
| Dyspnea | 0 (0) | 0 (0) | 0 (0) | NA |
| Intestinal symptom | 0 (0) | 0 (0) | 0 (0) | NA |
| Anosmia/dysgeusia | 1 (3) | 1 (5) | 1 (2) | 0.74 |
| Fatigue | 0 (0) | 0 (0) | 0 (0) | NA |
| Death/ARDS | 0 (0) | 0 (0) | 0 (0) | NA |
| MI/Stroke | 0 (0) | 0 (0) | 0 (0) | NA |
| DVT | 0 (0) | 0 (0) | 0 (0) | NA |
Data are presented as n (%) or mean ± standard deviation. NV: non-vaccines; OV: one-vacine; TV: two-vaccine; ARDS: acute respiratory distress syndrome; MI: myocardial infarction; DVT: deep vein thrombosis. p value, comparison among groups.